Related Experiment Video
Updated: Mar 8, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case
Michal Sarfaty1, Assaf Moore, Elizabeth Dudnik
1Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rationale:
Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for nonsmall cell lung cancer (NSCLC) as a second-line therapy.
Patient Concerns And Diagnosis:
We present a patient with squamous NSCLC, suffering from multiple bone and subcutaneous metastases.
Interventions:
The patient was treated with nivolumab.
Outcomes:
A subcutaneous lesion in her upper back grew substantially after the first cycle of nivolumab, and later regressed, with marked improvement in all cancer sites.
Lessons:
Such pseudoprogression may serve to predict subsequent clinical response.
More Related Videos
05:11Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
Published on: May 10, 2024
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
